JAZZ
Jazz Pharmaceuticals PLC
231.20$
-0.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 29.0% | 28.6% | 31.3% | 32.4% | 35.8% | 38.5% | 35.8% | 30.6% | 33.1% | 35.7% | 38.6% | 35.8% | |
| 11.9% | 10.6% | 12.7% | 11.9% | 18.1% | 20.1% | 16.1% | 10.9% | 10.9% | 11.9% | 15.6% | 14.6% | |
| 14.2% | 14.3% | 16.1% | 17.4% | 21.4% | 24.9% | 22.3% | 15.3% | 18.0% | 20.9% | 24.2% | 19.9% | |
| 5.6% | 6.2% | 6.2% | 6.1% | 5.9% | 6.0% | 5.7% | 6.5% | 6.7% | 7.1% | 7.1% | 7.9% | |
| 5.5% | 5.2% | 5.1% | 4.8% | 4.4% | 4.0% | 4.3% | 4.6% | 4.3% | 3.6% | 3.7% | 4.0% | |
| 2.6% | – | – | – | – | – | – | – | – | – | – | – | |
| 15.2% | 15.4% | 15.4% | 15.3% | 14.7% | 14.3% | 15.3% | 16.8% | 16.1% | 15.7% | 15.2% | 16.2% | |
| 48.4% | 47.6% | 46.2% | 44.7% | 42.0% | 39.6% | 40.9% | 43.6% | 40.2% | 38.0% | 35.4% | 36.4% | |
| 68.9% | 67.2% | 67.4% | 66.9% | 66.0% | 65.9% | 63.8% | 66.1% | 65.1% | 63.0% | 61.8% | 56.7% | |
| 14.0% | 13.5% | 13.8% | 13.7% | 8.4% | 8.6% | 10.6% | 18.9% | 20.0% | 19.2% | 18.9% | 20.1% | |
| 5.5% | 5.5% | 5.5% | 5.5% | 0.4% | 0.4% | 0.4% | 9.5% | 9.2% | 9.0% | 8.8% | 9.3% | |
| 1.0% | 0.9% | 0.7% | 0.9% | 0.7% | 0.6% | 0.8% | 0.8% | 1.3% | 1.0% | 0.8% | 1.2% | |
| 45.6% | 44.8% | 45.1% | 44.9% | 49.6% | 50.6% | 46.3% | 39.6% | 38.1% | 37.1% | 36.5% | 30.1% | |
| 31.1% | 32.8% | 32.6% | 33.1% | 34.0% | 34.1% | 36.2% | 33.9% | 34.9% | 37.0% | 38.2% | 43.3% | |
| 7.9% | 7.7% | 7.6% | 7.7% | 7.6% | 9.4% | 9.0% | 1.7% | 3.9% | 5.5% | 7.9% | 10.2% | |
| 0.6% | 0.6% | 0.6% | 0.6% | 0.5% | 0.5% | 0.5% | 0.6% | 0.5% | 0.5% | 0.6% | 0.6% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.